AbbVie News | finanzen.ch

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Orderbuch			Analysen
Historisch

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Orderbuch

Analysen

Historisch

19.12.17	AbbVie to Present at the Goldman Sachs 10th Annual Healthcare CEOs Unscripted: A View from the Top (PR Newswire)
18.12.17	Fresenius stellt Zulassungsantrag für Biosimilar-Generikum von AbbVie (AWP) Der Medizinkonzern Fresenius hat bei der Europäischen Arzneimittelagentur EMA erstmals einen Zulassungsantrag für ein sogenanntes Biosimilar gestellt, also ein Nachahmerprodukt biopharmazeutisch hergestellter Medikamente.» mehr
12.12.17	Genentech: Phase 3 Data Shows Venclexta Plus Rituxan Significantly Improved PFS (RTTNews)
12.12.17	Roche legt Daten aus MURANO-Studie mit Venclexta plus MabThera vor (AWP) Roche hat erste Daten aus der Phase-III-Studie MURANO am Fachkongress ASH (American Society of Hematology) vorgelegt.» mehr
12.12.17	AbbVie Announces Phase 3 Study of VENCLEXTA™/ VENCLYXTO™ (venetoclax) in Combination with Rituxan® (rituximab) Meets its Primary Endpoint (PR Newswire)
11.12.17	IMBRUVICA® (ibrutinib) Data Provide Insights Into Its Potential Treatment Benefits for Previously-Treated Chronic Graft-Versus-Host Disease -- A Serious, Possibly Life-Threatening Condition (PR Newswire)
09.12.17	IMBRUVICA® (ibrutinib) Pooled Analysis Suggests Benefit in Progression-Free Survival (PFS) at 3.5 Years in Patients with Relapsed/Refractory (R/R) Mantle Cell Lymphoma (MCL) (PR Newswire)
09.12.17	IMBRUVICA® (ibrutinib) Patient-Reported Outcomes Data Detail Long-Term Improvement in Treatment Outcomes and Quality of Life Experience in Chronic Lymphocytic Leukemia (CLL) Patients (PR Newswire)
05.12.17	IMBRUVICA® (ibrutinib) Plus Rituximab Phase 3 iNNOVATE Trial in Rare Waldenström's Macroglobulinemia Met Primary Endpoint (PR Newswire)
05.12.17	GALT Faces Big Test Today, ABBV Clears Psoriasis Trial, DEPO Cuts 40% Of Staff (RTTNews)
04.12.17	AbbVie: Risankizumab Meets Primary Endpoints In Fourth Phase 3 Psoriasis Study (RTTNews)
04.12.17	Risankizumab Meets All Primary Endpoints Reporting Positive Results in Fourth Pivotal Phase 3 Psoriasis Study (PR Newswire)
21.11.17	Roche und AbbVie kündigen für Fachkongress weitere Daten zu Venclexta an (AWP)
21.11.17	Phase 3 MURANO Study of Venetoclax Chosen as Late-Breaking Abstract at the 2017 American Society of Hematology Annual Meeting & Exposition, Highlighting AbbVie's Commitment to Helping Blood Cancer... (PR Newswire)
15.11.17	AbbVie to Present at the Evercore ISI 2017 Biopharma Catalyst/Deep Dive Conference (PR Newswire)
14.11.17	Drillisch werden in den MSCI World Index aufgenommen (Dow Jones)
14.11.17	Drillisch werden in den MSCI World Index aufgenommen (Dow Jones)
06.11.17	Lilly, Incyte: Baricitinib Shows Greater Improvements In Pain Control In RA (RTTNews)
03.11.17	AbbVie to Present at the Jefferies 2017 London Healthcare Conference (PR Newswire)
01.11.17	AbbVie Announces Positive Phase 3 Extension Study Data for Investigational Oral Treatment Elagolix for Management of Endometriosis with Associated Pain (PR Newswire)
30.10.17	FDA To Rule On Elagolix In Q2, More Light From CELG's RADIANCE, TGTX On Watch (RTTNews)
27.10.17	AbbVie Q3 Profit Tops View, Ups Dividend; Lifts FY Forecast - Quick Facts (RTTNews)
27.10.17	AbbVie Gets FDA Priority Review For Elagolix; Hikes Dividend - Quick Facts (RTTNews)
27.10.17	AbbVie Reports Third-Quarter 2017 Financial Results (PR Newswire)
27.10.17	AbbVie Increases Quarterly Dividend by 11 Percent (PR Newswire)
27.10.17	AbbVie Receives U.S. FDA Priority Review for Investigational Oral Treatment Elagolix for the Management of Endometriosis with Associated Pain (PR Newswire)
26.10.17	Risankizumab Meets All Co-Primary and Ranked Secondary Endpoints, Achieving Significantly Greater Efficacy Versus Standard Biologic Therapies in Three Pivotal Phase 3 Psoriasis Studies (PR Newswire)
25.10.17	Données sur le psoriasis des ongles maintenant comprises dans la monographie d'HUMIRA® (PR Newswire)
25.10.17	Nail psoriasis data now part of HUMIRA® label (PR Newswire)
25.10.17	Nail psoriasis data now part of HUMIRA® label (PR Newswire)
24.10.17	AbbVie to Showcase Robust Immunology Portfolio with New and Late-Breaking Data at the 2017 ACR/ARHP Annual Meeting (PR Newswire)
24.10.17	Alector and AbbVie Announce Collaboration to Advance a Novel Class of Immune Therapies for Patients with Alzheimer's Disease (PR Newswire)
18.10.17	AbbVie and Harpoon Therapeutics Announce Immuno-Oncology Research Collaboration (PR Newswire)
18.10.17	AbbVie to Present at the 2017 Credit Suisse Health Care Conference (PR Newswire)
11.10.17	AbbVie Demonstrates Leadership in HCV with New MAVYRET™ (glecaprevir/pibrentasvir) Data to be Presented at The Liver Meeting® 2017 (PR Newswire)
10.10.17	L'industrie nucléaire canadienne se réjouit du soutien ferme que le gouvernement accorde au secteur (PR Newswire)
10.10.17	AbbVie and Turnstone Biologics Announce Global Collaboration on Viral Immunotherapies in Oncology (PR Newswire)
09.10.17	AbbVie to Host Third-Quarter 2017 Earnings Conference Call (PR Newswire)
03.10.17	Bryan Benjamin Joins The Conference Board of Canada as Vice-President, Organizational Performance (PR Newswire)
02.10.17	Metro Supply Chain Group Appoints New U.S. Business Lead (PR Newswire)
30.09.17	Concours de l'Ordre national du mérite agricole - Le ministre Laurent Lessard rend hommage aux artisans du secteur agricole québécois (PR Newswire)
28.09.17	AbbVie Inc. -- Moody's: AbbVie's Humira patent settlement reduces uncertainty (Moodys)
28.09.17	Amgen, AbbVie Settle Litigation Regarding AMGEVITA - Quick Facts (RTTNews)
28.09.17	AbbVie Announces Global Resolution of HUMIRA® (adalimumab) Patent Disputes with Amgen (PR Newswire)
27.09.17	AbbVie Announces Approval of MAVIRET™ (glecaprevir/pibrentasvir) for the Treatment of Chronic Hepatitis C in All Major Genotypes (GT1-6) in Japan (PR Newswire)
22.09.17	AbbVie and Bristol-Myers Squibb Announce Clinical Research Collaboration to Evaluate a Therapeutic Regimen in Advanced Solid Tumors (PR Newswire)
21.09.17	Soleil Capital Corp. Announces Qualifying Transaction (PR Newswire)
20.09.17	Nominations du Conseil des ministres (PR Newswire)
18.09.17	Deck Design 101 (PR Newswire)
18.09.17	AbbVie Announces Positive Topline Results from Phase 3 Trial Evaluating VENCLEXTA™/VENCLYXTO™ (Venetoclax) Tablets in Combination with Rituxan® (rituximab) for the Treatment of Patients with... (PR Newswire)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Sonova Hldg	295.60	0.96 %	K V
Lonza Grp	531.00	0.53 %	K V
Alcon	76.02	0.34 %	K V
Roche Hldg G	247.40	0.28 %	K V
ABB	48.86	0.27 %	K V
Swisscom	498.40	-0.62 %	K V
UBS Group	26.71	-0.67 %	K V
Zurich Insur Gr	533.00	-0.97 %	K V
Holcim	86.10	-1.01 %	K V
Sika	213.20	-2.47 %	K V

mehr

11.11.24		Börse New York in Grün: S&P 500 zum Handelsende freundlich
11.11.24		Optimismus in New York: S&P 500 am Nachmittag mit Kursplus
11.11.24		NYSE-Handel: S&P 500 mittags freundlich
11.11.24		Freundlicher Handel: Börsianer lassen S&P 500 zum Start des Montagshandels steigen
02.07.24		Freundlicher Handel: S&P 500 verbucht zum Handelsende Zuschläge
02.07.24		Schwacher Handel in New York: S&P 500 beginnt die Sitzung mit Verlusten
06.05.24		S&P 500-Titel AbbVie-Aktie: Mit dieser Dividende bereitet AbbVie Aktionären eine Freude
26.04.24		Gewinne in New York: S&P 500 am Nachmittag fester

11.11.24

Börse New York in Grün: S&P 500 zum Handelsende freundlich

11.11.24

Optimismus in New York: S&P 500 am Nachmittag mit Kursplus

11.11.24

NYSE-Handel: S&P 500 mittags freundlich

11.11.24

Freundlicher Handel: Börsianer lassen S&P 500 zum Start des Montagshandels steigen

02.07.24

Freundlicher Handel: S&P 500 verbucht zum Handelsende Zuschläge

02.07.24

Schwacher Handel in New York: S&P 500 beginnt die Sitzung mit Verlusten